Introduction
Invasive candidiasis is a leading cause of mortality worldwide, being Candida albicans the predominant cause of candidemia and invasive candidiasis. However, candidiasis due to non-C. albicans species, such as Candida parapsilosis, Candida glabrata, Candida tropicalis, Candida krusei, Candida lusitaniae, Candida guilliermondii, are increasing. Some of these species exhibit resistance or reduced susceptibility to fluconazole and other triazoles, echinocandins or amphotericin B. C. parapsilosis is associated to infections in neonates and young adults, usually related to the presence of central venous catheter and hyperalimentation [1] . C. parapsilosis is usually susceptible to most antifungal agents, but there are reports of infections caused by isolates with decreased susceptibility to azoles and echinocandins [2] . Molecular identification methods have unveiled new cryptic species within C. albicans and C. parapsilosis species complexes, such as Candida dubliniensis and Candida africana within the C. albicans complex or Candida metapsilosis and Candida orthopsilosis within C. parapsilosis complex. These cryptic species show differences in antifungal susceptibility and virulence, being their epidemiology and antifungal susceptibility a matter of increased interest [3] [4] [5] .
Micafungin inhibits the synthesis of 1,3-β-D-glucan, an essential molecule of many pathogenic fungi wall architecture, and exhibits an excellent activity against a great number of Candida species many resistant to azoles [6] . Thus, micafungin is a very useful drug for the first line therapy of invasive candidiasis [7] .
Postantifungal effect (PAFE) allows for sustained killing of fungus when it is exposed briefly to an antifungal, being a concentration-dependent process [8] . The existence of PAFE depends on both the fungal species and the class of the antifungal drug. Whereas antifungal drugs that have long PAFE may be given less frequently, the antifungal drugs with short PAFE may require a frequent administration [9] . For this reason, the PAFE may have a main clinical relevance in the design of dosing regimens for antifungal agents, such as micafungin. The PAFE of micafungin against various species of Candida has been evaluated in a few studies [10] [11] [12] [13] . The aim of this study was to determinate the PAFE of micafungin against the species inside of the C albicans and C parapsilosis complexes. Isolates were identified by their metabolic properties using the ATB ID 32C method (bioMérieux, Marcy l'Étoile, France) and by molecular methods, as previously described [14, 15] .
Materials and Methods

Microorganisms
Antifungal Agents
Micafungin (Astellas Pharma, Madrid, Spain) was dissolved in dimethyl sulfoxide (DMSO), to obtain a stock solution of 5120 μg/ml. The dilutions were prepared in RPMI 1640 medium with L-glutamine, 0.2% glucose and without NaHCO 2 buffered to pH 7 with 0.165 M morpholinepropanesulfonic acid (MOPS) (Sigma-Aldrich, Madrid, Spain). Stock solutions were stored at -80°C until use. 
In Vitro Susceptibility Testing
MICs, defined as minimum concentrations that produce 50 growth reduction, were determined following M27-A3 and M27-A3 S4 documents [16, 17] . All MICs were measured in RPMI 1640 medium buffered to pH 7.0 with 0.165 M MOPS and results were read after 24 h of incubation.
Time-Kill Procedures
Time-kill studies (TK) were performed as previously described [18] [19] [20] . Strains were subcultured on Sabouraud dextrose agar (SDA) plates prior to testing. Cell suspensions were prepared in sterile water by picking 3 to 5 colonies from a 24 h culture and the resulting suspension was prepared at 1 McFarland ( 10 6 CFU/ml). One milliliter of the cell suspension was added to vials containing 9 ml of RPMI. TK were carried out on microtiter plates for the BioScreen C computer-controlled microbiological incubator (BioScreen C MBR, LabSystems, Helsinki, Finland) in RPMI (final volume 200 μl) by using an inoculum of 1-5 x 10 5 CFU/ml. On the basis
of MICs, micafungin concentrations tested were 0.12, 0.5 and 2 μg/ml for the C. albicans complex and 0.25, 2 and 8 μg/ml for the C. parapsilosis complex. These micafungin concentrations are achieved in serum after standard therapeutic doses [21] . Inoculated plates were incubated 48 h at 36 ± 1°C (30 ± 1°C for C. africana). At predetermined time points (0, 2, 4, 6, 24, and 48 h), 10 μl (0-6 h) or 6 μl (24-48 h) were collected from each culture well (control and test solution wells), serially diluted in phosphate buffered saline (PBS) and aliquots plated onto SDA. The lower limit of accurate and reproducible detectable colony forming units (CFU) counts was 200 CFU/ml. When the CFUs were expected to be less than 200 per milliliter, samples of 5 μl were taken directly from the test solution and plated. After incubation of the plates at 36 ± 1°C for 48 h (30 ± 1°C for C. africana), Candida colonies were counted. Each experiment was performed twice for each isolate. Plots of averaged colony counts (log10 CFU/ml) versus time were constructed and compared against a growth control (in the absence of drug). Also the antifungal carryover effect was determined as formerly reported [22] .
PAFE
PAFE studies were performed as described previously with slight differences [23] . Standard 1 McFarland turbidity cell suspensions were prepared in sterile distilled water, from which 1 ml was added to 9 ml of RPMI. Micafungin concentrations were the same as described for the TK.
Following an incubation of 1 h, micafungin was removed by a process of 3 cycles of repeated centrifugations (2000 rpm, 10 min) and washed with PBS. After the final centrifugation, the fungal pellet was suspended in 600 μl of RPMI. All samples were incubated on microtiter plates for the BioScreen C at 36 ± 1°C, with a final volume of 200 μl. At the same predetermined time points described for the TK, samples were serially diluted in PBS and inoculated onto a SDA plate for CFU counting. When the colony counts were expected to be less than 200 CFU/mL, samples of 5 μl were taken directly from the test solution and plated. After incubation of the plates at 36 ± 1°C for 48 h, Candida colonies were counted. The lower limit of accurate and reproducible detectable colony counts was 200 CFU/ml. PAFE was calculated for each isolate as the difference in time required for control (in the absence of drug) and treated isolates to grow 1 log 10 following drug removal. PAFE was also determined using the following equation: PAFE = T-C, where T = time required for counts in treated cultures to increase by 1 log 10 unit above that seen following drug removal and C = time required for counts in control to increase by 1 log 10 unit above that following the last washing.
PAFE and TK data comparison
Fungicidal activity was described as a 3 log 10 (99.9%) reduction, and fungistatic activity was defined as a < 99.9% reduction in CFU from the starting inoculum size [24] . Plots of averaged colony counts (log10 CFU per milliliter) versus time were constructed and compared against a growth control. The ratios of the log killing during PAFE experiments to the log killing during time kill experiments were calculated. Time-kill and PAFE experiments were performed simultaneously.
Statistical Analysis
Analysis of variance was performed to determine significant differences in PAFE (in hours) among species and concentrations, using GraphPad Prism 5.01 (GraphPad Software, San Diego, CA; USA). A p value < 0.05 was considered significant.
Results
No antifungal carryover effect was detected in TK. Micafungin MICs for isolates from C. albicans and C. parapsilosis complexes are shown in Table 1 .
The results of TK and PAFE experiments for C. albicans, C. dubliniensis and C. africana are shown in Table 2 . Micafungin showed prolonged PAFE ( 37.5 h) against all strains of C. albicans complex with 2 μg/ml (p < 0.0001). With one of these strains (UPV/EHU 99-101) PAFE was > 43 h with 0.5 μg/ml. During TK tests, micafungin was fungicidal against 5 out of 14 (36%) strains of C. albicans complex (C. albicans NCPF 3156, UPV/EHU 99-101, 99-102, 99-105 and C. dubliniensis UPV/EHU 00-135). The extent of micafungin log-killing in TK ranged from 0.08 to 5.22 log at 2 μg/ml. After micafungin removal in PAFE experiments, fungicidal endpoint was achieved against 2 out of 14 (14%) strains of C. albicans complex (C. albicans UPV/EHU 99-102 and C. dubliniensis UPV/EHU 00-135). Moreover, the extent of killing during PAFE experiments ranged from 0.28 to 4.67 log with 2 μg/ml. The mean value of PAFE/TK ratio was 43.25 (with 2 μg/ml) for C. albicans complex. Against 4 out of 14 strains (29%), the PAFE/TK ratio of micafungin at the highest tested concentration was 100, indicating that 1-hour exposure to micafungin accounted for up to 100% of the overall killing observed during TK. Additionally, a ratio of 100 at concentrations 2 μg/m was observed for C. africana (Table 2) . Table 3 summarizes the results of time-kill and PAFE experiments for C. parapsilosis, C. metapsilosis and C. orthopsilosis at each micafungin concentration. During TK, micafungin at 8 μg/ml caused significant reductions from the starting inoculum of each strain, with a killing activity that ranged from 1.67 to 5.43 log. However, during PAFE experiments, 1-hour exposure of the strains to micafungin did not cause important reductions in colony counts. PAFE of micafungin ranged 3.8 to 15.7 h (with 8 μg/ml); the longest PAFE (15.7 h) was reached against C. parapsilosis UPV/EHU 09-378. Micafungin at 8 μg/ml demonstrated fungicidal activity in TK against 4 out 7 (57%) strains from C. parapsilosis complex (C. parapsilosis UPV/EHU 09-378, C. metapsilosis ATCC 96143, UPV/EHU 07-045 and C. orthopsilosis ATCC 96139). However, after micafungin removal in PAFE experiments, it was not reached fungicidal endpoint against any of the tested strains. The lack of similarity between TK and PAFE data was also detected in the mean PAFE/TK ratio of 0.49, with 8 μg/ml, suggesting that 1-hour exposure to micafungin accounted for only a 2% of the overall killing observed during time-kill experiments; only one strain, C. parapsilosis UPV/EHU 09-378, showed a ratio of 100, with 2 μg/ml (Table 3) . PAFE results for C. albicans complex (41.83 ± 2.18 h) differed from C. parapsilosis complex (8.07 ± 4.2 h) with the highest concentration of micafungin tested (p < 0.0001). This difference is also evident when comparing C. albicans and C. parapsilosis complexes curves from PAFE assays (Figs 1 and 2) . Micafungin caused lethality (with 2 μg/ml) against C. albicans complex (Fig 1) that persisted during the 48 h testing period; however, in Fig 2 similar log (CFU/ml) slopes between micafungin and control can be observed.
Discussion
TK and PAFE experiments of micafungin against Candida have usually included a low number of isolates [10] [11] [12] [13] . This is the first study that has evaluated PAFE of micafungin against C. dubliniensis, C. africana, C. metapsilosis and C. orthopsilosis. C. dubliniensis and C. africana are cryptic species from C. albicans. Similarly C. metapsilosis and C. orthopsilosis are cryptic species from C. parapsilosis. These species have different in vitro susceptibility to antifungal agents [3, 4, 25] . Additionally, PAFE is an important factor in both dose interval choice and outcome.
MICs for C. albicans and C. parapsilosis complexes were consistent with other studies of micafungin activity in vitro against these species [26] . Moreover, we also found that micafungin reached fungicidal endpoint against 4 out of 7 strains of C. albicans (with 2 μg/ml) and against 1 out of 3 strains of C. parapsilosis (with 8 μg/ml), during TK experiments. This fungicidal activity has also been reported by Smith et al. [11] against both species.
After micafungin removal, Nguyen et al. [11] observed fungicidal activity against 1 out 4 strains of C. albicans, 1 out of 3 strains of C. parapsilosis, 2 out of 3 strains of C. glabrata and 1 out of 2 strains of C. krusei (with range concentrations 0.12 to 8 μg/ml). Similarly, in the current study, the fungicidal endpoint was reached against 1 out of 7 strains of C. albicans at the highest tested concentration (2 μg/ml). Nevertheless, after micafungin removal, no fungicidal endpoint was achieved against C. parapsilosis [11] .
Micafungin (8 μg/ml) displayed PAFE against C. parapsilosis complex that ranged from 3.8 to 15.7 h, being the longest PAFE against C. parapsilosis UPV/EHU 09-378. These results are similar to previous reported by Smith et al. [10] Other authors have demonstrated that a short exposure (1 h) of C. albicans to low concentrations (0.125 to 1 μg/ml) of micafungin, resulted in a PAFE of 5 h [12] . Our current findings demonstrate that micafungin produced a longer PAFE against C. albicans than those previously reported, being the PAFE > 40 h with 2 μg/ml against all strains. Manavathu et al. [12] compared PAFE of different antifungal drugs against C. albicans and Aspergillus fumigatus and stated that antifungal drugs with fungicidal activity tend to possess longer PAFE than fungistatic ones. On the other hand, Ernst et al. [23] observed that fluconazole displayed no measurable PAFE against none of the studied microorganisms, while echinocandins displayed prolonged PAFE of greater than 12 h against C. albicans with concentrations 0.12 μg/ml. Our current findings differed from these ones, as no measurable PAFE was detected against C. albicans at such low micafungin concentrations (0.12 μg/ml) except for one strain, UPV/EHU 99-102. In order to investigate the effect of exposure time on the observed PAFE, Ernst et al. studied the PAFE of caspofungin and amphotericin B after 0.25, 0.5 and 1 h exposure times concluding that PAFE was not affected by the exposure time: 0.25 h exposure produced the same PAFE as 1 h exposure [23] . Similarly, Moriyama et al. reported that the maximum PAFE against Candida occurred with caspofungin exposures of 5 or 15 minutes [8] . As performed in other PAFE experiments, in which PAFE was determined after 1 h exposure [10] [11] [12] , we have studied the PAFE of micafungin after 1 h exposure.
In another study, Ernst et al. also found PAFE with micafungin against C. albicans, C. krusei, C. tropicalis and C. glabrata, [13] . Micafungin and anidulafungin had greater activity than caspofungin, and none of the echinocandins depicted fungicidal activity against C. parapsilosis. However, the three echinocandins reached the fungicidal endpoint against C. orthopsilosis and C. metapsilosis [19] . Results from our study differ from these reports as we have found that micafungin was fungicidal only against one strain of C. parapsilosis.
Previous studies have evaluated PAFEs of anidulafungin and caspofungin against Candida, and have shown that anidulafungin achieved fungicidal activity against C. parapsilosis, but not against C. albicans, and caspofungin did not show fungicidal activity [27, 28] .
Our PAFE studies demonstrated that micafungin produced concentration-dependent, strain-dependent and complex-dependent antifungal activity following drug removal. PAFE was measurable at the higher concentration, and this effect was enhanced by increasing the concentration of the antifungal drug, with highest concentration resulting in the longest PAFE in each case. One of the most notable findings of this study was the PAFE of micafungin against C. albicans complex. Micafungin exerted prolonged PAFE against C. albicans complex, and 1 h exposure to micafungin accounted for up to 100% of the overall killing observed during TK experiments in 29% of the studied strains. The results are consistent with a rapid onset of anticandidal activity of micafungin, which might be explained by a rapid association with its target (1,3-β-D-glucan synthase). Alternatively, it has also been suggested that the drug, as a large lipopeptide with a fatty acid side chain, could rapidly intercalate with the phospholipid bilayer of the Candida cell membrane and subsequently access its target over time [29] . Recently, Ellepola et al. studied the PAFE of nystatin, amphotericin B, ketoconazole and fluconazole against oral C. dubliniensis isolates, concluding that nystatin, amphotericin B and ketoconazole produced a detectable PAFE, whereas fluconazole did no display any measurable PAFE [30, 31] . This finding is consistent with previously published by Ernst et al. [23] . Kovács et al. reported caspofungin PAFE in 2 C. albicans strains [32] .
In conclusion, micafungin showed significant differences in PAFE against C. albicans and C. parapsilosis complexes, being PAFE of micafungin for the C. albicans complex longer than against the C. parapsilosis complex. These differences in the PAFE could be explained by the distinct microorganism growth characteristics, the antifungal drug binding affinity to the targets, or differences in the amount of β-glucan in the fungal cell wall. These PAFE differences for C. parapsilosis and other Candida species might have important therapeutic implications. The current data could be useful in optimizing dosing regimens for micafungin against C. albicans, C. dubliniensis, C. africana, C. parapsilosis, C. metapsilosis and C. orthopsilosis. However, further animal studies and human clinical trials are needed to explore their potential clinical usefulness and applications.
